Education
About Us
Working with TipRanks
Follow Us
Pulse Biosciences (PLSE)
NASDAQ:PLSE
Earnings Data
Report Date
May 07, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
―Last Year’s EPS
-0.15Same Quarter Last Year
Based on 0 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 27, 2025
|% Change Since: 2.43%
|Next Earnings Date:May 07, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in product development and commercialization, particularly in the advancement of their nsPFA technology. Financially, the company strengthened its balance sheet, although it also faced increased expenses and net losses. The sentiment of the call is balanced, with notable achievements in clinical and financial aspects, but also challenges in managing increased operational costs.Company Guidance
During the Pulse Biosciences Fourth Quarter 2024 Earnings Conference Call, CEO Paul LaViolette highlighted several key metrics and advancements. The company achieved seven FDA clearances, treated 6,000 patients, and secured FDA breakthrough device designation for its cardiac surgical clamp. Financially, total GAAP costs and expenses rose to $20.3 million from $12.5 million year-over-year, with non-GAAP costs reaching $11.3 million. The GAAP net loss increased to $19.4 million, while the non-GAAP net loss was $10.4 million. Importantly, Pulse Biosciences reinforced its balance sheet, ending 2024 with $118 million in cash and equivalents, driven by $47.9 million in net proceeds from warrant exercises related to the July 2024 rights offering.Advancements in Nanosecond PFA Technology
Pulse Biosciences is making progress in early commercialization steps with their Percutaneous Electrode for soft tissue ablation and executing clinical feasibility studies with the surgical clamp and 360 Catheter for atrial fibrillation treatment.
Successful Clinical Data Presentations
Clinical data from the nsPFA 360 Catheter was presented at the AF Symposium, and data on benign thyroid nodule ablation was presented at the American Thyroid Association and North American Society of Interventional Thyroidology.
Financial Strength and Strategy
The company raised an additional $47.9 million through warrant exercises related to a rights offering, strengthening their balance sheet with $118 million in cash and equivalents as of December 31, 2024.
---
PLSE Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
PLSE Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 27, 2025 | $15.66 | $16.60 | +6.00% |
| Oct 30, 2024 | $17.72 | $17.43 | -1.64% |
| Aug 12, 2024 | $15.65 | $16.91 | +8.05% |
| May 07, 2024 | $7.60 | $6.90 | -9.21% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Pulse Biosciences (PLSE) report earnings?
Pulse Biosciences (PLSE) is schdueled to report earning on May 07, 2025, TBA Not Confirmed.
What is Pulse Biosciences (PLSE) earnings time?
Pulse Biosciences (PLSE) earnings time is at May 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PLSE EPS forecast?
Currently, no data Available
---